Pathogenic Hh pathway activation may occur in cancer at several levels of the Hh signal transduction cascade, including mutations in Ptch1, Smo, and Sufu, as well as amplification of Gli1 [12,29,43,44,45,46]. This evidence concerns the gene SUFU and cancer.